Abstract 255P
Background
CPS+EG scoring system properly defined prognosis subgroups of early breast cancer (eBC) patients (pts) treated with neoadjuvant chemotherapy (NACT) with a higher CPS+EG associated with worse outcomes. It remains unknown if CPS+EG similarly stratify prognostic in HER2-low and HER2-zero eBC patients after NACT.
Methods
This pluricenter french retrospective study included eBC pts treated with NACT from 2 cohorts, a monocenter local database at CGFL, Dijon and a pluricenter clinical trial PRIMUNEO (NCT01513408). Molecular features were determined on core biopsies. Threshold for HR positivity was ≥10%. HER2-low/zero status was defined by immunohistochemistry (IHC) HER2 staining. CPS+EG score was calculated for all pts with available data.
Results
608 patients with HER2-negative eBC that have received NACT were included. Median age at diagnosis was 51.0 y-o. Nearly all pts (98.2%) received >3 NACT cycles. In the overall population, 288 pts (47.4%) were HER2-low. More pts were HR+ than TNBC with 367 (60.3%) and 241 pts (39.7%), respectively. The majority of pts harboring HR+ disease were HER2-low (61.0%) contrary to TNBC eBC pts (26.5%). In the HER2-low and HER2-zero population, CPS+EG was able to well categorized pts within prognosis subgroups (log-rank p <0.0001). Table: 255P
| CPS+EG HER2-low (n =288) | CPS+EG HER2-zero (n =320) | |
| Score | 5-year DFS rate (%) (95% CI) | 5-year DFS rate (%) (95% CI) |
| 0 | 100 (100-100) | 100 (100-100) |
| 1 | 92.9 (82.14-97.28) | 86.11 (74.1-92.81) |
| 2 | 71.95 (60.8-80.43) | 86.8 (77.89-92.3) |
| 3 | 69.78 (58.09-78.8) | 72.5 (61.18-81.01) |
| 4 | 48.03 (29.17-64.63) | 55.48 (40.12-68.39) |
| 5 | 38.1 (8.92-68.02) | 30.77 (9.5-55.43) |
In HR+/HER2-negative pts, CPS+EG still properly separated pts within prognosis subgroups between HER2-low and HER2-zero pts (log-rank p =0.0012 and p <0.0001, respectively). In TNBC population, CPS+EG appears to be less accurate. Within HR+ and TNBC molecular subtypes, there was no difference in 5-year DFS between HER2-low and HER2-zero pts harboring a similar CPS+EG score.
Conclusions
In this study, we show that the CPS+EG scoring system retains its interest for the prognostic stratification of pts treated with NACT for HER2-low and HER2-zero eBC. While it seems especially true for HR+ disease, CPS+EG appears to be less effective for TNBC in isolating different outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
304P - Generalizability of 313-SNP PRS for breast cancer risk in non-European ancestries
Presenter: Helen Shang
Session: Poster session 02
305P - Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
Presenter: Sora Kang
Session: Poster session 02
307P - Identifying new biological subgroups of triple-negative breast cancer using next-generation integrative clustering pipeline
Presenter: Xixuan Zhu
Session: Poster session 02
308P - Regression-based deep-learning predicts breast cancer recurrence risk score from pathology slides
Presenter: Omar El Nahhas
Session: Poster session 02
310P - Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay
Presenter: Mitchell Elliott
Session: Poster session 02
311P - Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on the genetic counselling experience
Presenter: Ranjit Kaur
Session: Poster session 02
312P - Prediction model of breast cancer patient’s neoadjuvant treatment outcome using breast cancer organoids cultured from core needle biopsies
Presenter: Dong Woo Lee
Session: Poster session 02
313P - Intrinsic subtypes in a cohort of early breast cancer patients
Presenter: Theresa Bracht
Session: Poster session 02